Jiedu Xiaozheng Yin Induces M1 Macrophage Polarization via TLR4 in Colitis-Associated Colorectal Cancer

Study Background and Research Question

Colitis-associated colorectal cancer (CAC) represents a highly malignant form of colorectal cancer with significant therapeutic challenges, driven in part by the tumor-promoting inflammatory microenvironment. Recent advances have focused on modulating the immune milieu, particularly macrophage polarization states, as a strategy for suppressing tumor progression. Macrophages exhibit functional plasticity, existing primarily as classically activated M1 (pro-inflammatory, anti-tumorigenic) or alternatively activated M2 (anti-inflammatory, tumor-promoting) phenotypes. The mechanisms governing their polarization—and the means to therapeutically direct these states—remain a critical area of investigation. Traditional Chinese medicine (TCM), specifically Jiedu Xiaozheng Yin (JXY), has shown multi-faceted anti-tumor effects, but its influence on macrophage-mediated immune modulation in CAC required clarification. The central research question addressed by Liu et al. (2024) was whether JXY could inhibit CAC progression by promoting M1 macrophage polarization, and if so, through which molecular pathways according to the reference study.

Key Innovation from the Reference Study

The principal innovation of this study is the mechanistic linkage between JXY administration and the reprogramming of intestinal mucosal macrophages toward an M1 phenotype via TLR4 signaling. This represents a notable advance in understanding how complex botanical formulations can modulate innate immune cell states to produce anti-tumor effects. The researchers utilized both in vivo and in vitro systems to establish not only the phenotypic switch but also the functional consequences—specifically, suppression of tumor progression in a CAC mouse model. The study further dissected the requirement of intact TLR4 signaling for this immune modulation, providing a clear molecular target for future therapeutic integration.

Methods and Experimental Design Insights

Liu et al. employed a multi-layered approach to dissect JXY's effects. An orthotopic mouse model of CAC was established to recapitulate the pathophysiological context of colitis-driven tumorigenesis. Pathological evaluations included measurement of colon length, tumor burden, and calculation of organ indices for the liver, spleen, and thymus. Histological changes were characterized by H&E staining, while immunohistochemistry (IHC) was used to localize and quantify M1 and M2 macrophage subsets in colonic tissue.

In vitro, the RAW264.7 murine macrophage cell line was treated with JXY, and polarization was assessed using reverse transcription-quantitative PCR (RT-qPCR) and flow cytometry. Markers for M1 polarization (IL-1β, TNF-α, iNOS, CD80, CD86) and M2 polarization (Arginase-1, CD206, IL-10) were measured, alongside functional assays of phagocytic capacity. Importantly, the study interrogated the TLR4 pathway's role using specific antagonists—including KG-501, a small-molecule inhibitor of CREB-mediated transcription and transcriptional coactivator disruption, as well as TAK242, PDTC, SR11302, and LY294002—to determine whether blockade of this axis would abrogate JXY-induced macrophage reprogramming.

Core Findings and Why They Matter

The study's core findings are as follows:

• JXY treatment significantly reduced tumor number and ameliorated colonic lesions in the CAC mouse model, as measured by colon length and histopathological assessment (Liu et al., 2024).
• JXY induced a marked shift in the macrophage population toward the M1 phenotype within the intestinal mucosa, evidenced by increased expression of M1 markers (IL-1β, TNF-α, iNOS, CD80, CD86) and enhanced phagocytic function.
• Concomitantly, JXY suppressed M2-associated markers (Arg-1, CD206, IL-10), suggesting a reprogramming away from the tumor-promoting phenotype.
• Pharmacological inhibition of the TLR4 pathway, including the use of transcriptional coactivator disruptors such as KG-501, diminished the effect of JXY on M1 polarization and reduced the expression of M1-related cytokines (IL-6, TNF-α, iNOS, IL-1β), demonstrating that TLR4 signaling and downstream transcriptional regulation are essential for JXY’s immunomodulatory action.

This mechanistic insight is meaningful for the field of tumor immunology and epigenetic regulation, as it connects innate immune reprogramming to the disruption of transcriptional coactivator networks—an emerging theme in cancer biology. The use of small-molecule modulators, such as 3-((4-chlorophenyl)carbamoyl)naphthalen-2-yl dihydrogen phosphate (KG-501), to interrogate these pathways further highlights the translational potential of targeting the CREB-CBP axis in oncogenic signaling and macrophage polarization.

Comparison with Existing Internal Articles

The findings of Liu et al. align with existing internal resources. For example, the article "Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization via TLR4 in CAC" emphasizes the capacity of JXY to reshape the tumor microenvironment through immune modulation, reinforcing the central role of macrophage phenotype in therapeutic response. Additional coverage, such as "KG-501: Unlocking CREB-Myb Axis Disruption for Translational Oncology", provides context for the use of transcriptional coactivator disruption—using small molecules like KG-501—as a means to dissect and manipulate oncogenic and epigenetic regulatory circuits. These resources collectively underscore the value of combining immune-targeted therapies with precision modulators of transcriptional machinery, especially in complex disease models like CAC.

Limitations and Transferability

Despite its robust mechanistic insights, the study is subject to several limitations. The reliance on mouse models and murine macrophage cell lines may not fully capture the heterogeneity and complexity of human tumor-immune interactions. Additionally, JXY is a multi-component formulation whose specific active constituents remain to be identified, raising questions about reproducibility and standardization. The use of pathway inhibitors—while informative—can have off-target effects that confound interpretation. Transferability to clinical settings will require further validation in human systems, as well as exploration of pharmacokinetics and potential toxicity associated with both JXY and pathway-targeting agents. Nonetheless, the demonstration of TLR4-dependent, M1 polarization-mediated tumor suppression provides a clear rationale for translational exploration.

Protocol Parameters

• JXY administration in vivo: Dosage and treatment schedules as outlined by Liu et al. (2024). Monitor colon length, tumor number, and organ indices post-treatment.
• Macrophage polarization assessment in vitro: Culture RAW264.7 cells; treat with JXY or controls; evaluate polarization using RT-qPCR for M1 (IL-1β, TNF-α, iNOS, CD80, CD86) and M2 (Arg-1, CD206, IL-10) markers; assess phagocytic function using standard bead uptake assays.
• Pathway inhibition: Employ KG-501 at literature-reported concentrations (e.g., low micromolar range, as per product information), alongside other inhibitors such as TAK242, to interrogate TLR4 and downstream transcriptional networks.

Research Support Resources

To support replication or extension of these findings, researchers may consider the use of selective transcriptional coactivator disruptors, such as KG-501 (SKU B8380). KG-501, also known as 3-((4-chlorophenyl)carbamoyl)naphthalen-2-yl dihydrogen phosphate, is a small-molecule inhibitor that blocks CREB-mediated transcription and interferes with Myb-KIX domain interactions, functioning as an epigenetic regulation modulator and oncogenic signaling pathway inhibitor. Details regarding biological activity and recommended experimental use can be found in the APExBIO product dossier. Integrating such tools can facilitate the study of macrophage polarization, transcriptional regulation, and tumor microenvironment modulation in preclinical models.